TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2863392
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (dezocine and morphine)
Study: 29176383
Drug: Jump Interval
Normalized name: Minerval
DrugBank: Idroxioleic acid (DB18213)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Jump Interval Training (JIT) - performed twice per week, consisting of 4-6 bouts of continuous vertical jumping (30 seconds) with 5-minute intervals
Study: 24485479
Drug: Clonidine (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clonidine (0.15 mg orally)
Study: 22961867
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral antioxidant cocktail (AOC) consisting of vitamin C, E, and α-lipoic acid
Study: 20591671
Drug: ST/G reconstruction
Approvals — FDA: no, EMA: no, PMDA: no
Description: ST/G reconstruction
Study: 18093299
Drug: Cryokinetic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cryokinetic treatment (intermittent ice applications with compression and therapeutic exercise)
Study: 11155139
Drug: Systemic interferon‐alpha‐2A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic interferon‐alpha‐2A treatment
Study: 29111889
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement containing raspberry ketone, capsaicin, caffeine, garlic, and Citrus aurantium (EXP)
Study: 29111889
Drug: Dietary supplement
Normalized name: dietary supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary supplement (EXP)
Study: 24694358
Drug: Vicco(®) turmeric
Normalized name: Turmeric
DrugBank: Turmeric (DB14276)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vicco(®) turmeric cream (VTC) applied five times a day
Study: 20706632
Drug: Peptide vaccine
Normalized name: E39 peptide vaccine
DrugBank: GALE-301 (DB17262)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peptide vaccine (1 or 4 mg)
Study: 17510493
Drug: L-lysine (2.64
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-lysine (2.64 g per day) and L-arginine (2.64 g per day)
Study: 29726939
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg every 12 weeks (q12w)
Study: 29726939
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg every 8 weeks (q8w)
Study: 30375189
Drug: Adenosine-loaded DMN
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine-loaded DMN (Ad-DMN) patches and topical adenosine-loaded cream (Ad-cream)
Study: 30375189
Drug: Topical adenosine-loaded
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical adenosine-loaded cream (Ad-cream)
Study: 21234793
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n=30) participated in three weekly group sessions followed by three weekly follow-up telephone calls over six weeks.
Study: 18300284
Drug: Phenserine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenserine (30 mg/day)
Study: 10391179
Drug: P‐IGIV 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐IGIV 1500 mg/kg
Study: 10391179
Drug: P‐IGIV 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐IGIV 750 mg/kg
Study: 10391179
Drug: P‐IGIV 250
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐IGIV 250 mg/kg
Study: 9627768
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER (2.5 mg)
Study: 18831357
Drug: Ramipril (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril (2.5 mg)
Study: 9010611
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (Felodipine ER 2.5 mg / Ramipril 2.5 mg)
Study: 9052345
Drug: Felodipine ER
Normalized name: Felodipine ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Felodipine ER monotherapy
Study: 2005326
Drug: Local immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local immunotherapy (LIT) with Dermatophagoides extract
Study: 319424
Drug: Indomethacin (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Indomethacin (150 mg daily)
Study: 23152865
Drug: Real acupuncture
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real acupuncture (RA) and treatment instruction (TI)
Study: 23152865
Drug: Real acupuncture
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real acupuncture (RA) and non-treatment instruction (NI)
Study: 23152865
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture (SA) and treatment instruction (TI)
Study: 23152865
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture (SA) and non-treatment instruction (NI)
Study: 1928019
Drug: Relapse Prevention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relapse Prevention Therapy (RPT)
Study: 15983299
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg once daily for 12 weeks followed by 45 mg once daily for an additional 12 weeks
Study: 15983299
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg once daily followed by 4 mg twice daily for the same intervals
Study: 12464326
Drug: Haloperidol (dopamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (dopamine D2-receptor antagonist)
Study: 10603715
Drug: CIC antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CIC antibody levels during leprosy reactions
Study: 7860911
Drug: Sotalol (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotalol (320 mg twice daily)
Study: 1781047
Drug: RT (no
Normalized name: PIGGYBACK WITH VIAL PORT (NON-THREADED)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RT (no further therapy)
Study: 6109587
Drug: 5-mg oral
Normalized name: Augmentin 875-mg Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-mg oral doses of prazosin
Study: 30649458
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of tapentadol
Study: 30649458
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg of tramadol
Study: 30649458
Drug: Inert placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inert placebo (calcium tablets)
Study: 30463785
Drug: Rectal washout
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal washout with povidone‐iodine (RW‐PI)
Study: 30463785
Drug: Rectal washout
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal washout with Ringer solution with an irrigation instrument (RW‐R)
Study: 30463785
Drug: Rectal washout
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal washout with Ringer solution without an irrigation instrument (RW)
Study: 16569820
Drug: Maribavir 400
Normalized name: MARIBAVIR
DrugBank: Maribavir (DB06234)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maribavir 400 mg twice daily for 10 days
Study: 12972305
Drug: Normal haemoglobin
Normalized name: Abnormal haemoglobin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal haemoglobin group (>/=13 g/dl in males, >/=12 g/dl in females)
Study: 12972305
Drug: Anaemic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anaemic group (<13 g/dl in males, <12 g/dl in females)
Study: 10548200
Drug: Dopexamine infusion
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine infusion (0.5, 1.0, 2.0, and 4.0 microg/kg/min)
Study: 7936339
Drug: Dopexamine infusion
Normalized name: dopexamine
DrugBank: Dopexamine (DB12313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dopexamine infusion
Study: 8740612
Drug: Epidural lignocaine
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural lignocaine (40 mg)
Study: 8740612
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonidine (150 micrograms) and lignocaine (40 mg)
Study: 8740612
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of clonidine and lignocaine
Study: 25693652
Drug: All injections
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All injections
Study: 30790690
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral P2Y12 inhibitors)
Study: 12919177
Drug: Complementary medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complementary medicine
Study: 11080723
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of MSG
Study: 11080723
Drug: Increasing doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increasing doses of MSG
Study: 11080723
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g of MSG with food
Study: 8445420
Drug: Tamoxifen (Tam)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (Tam) 30 mg/d for 2 years
Study: 3885700
Drug: Propafenone, 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone, 300 mg every 8 hours
Study: 3885700
Drug: Disopyramide, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide, 200 mg every 8 hours
Study: 26905433
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium at 1.25 mmol/l
Study: 26905433
Drug: Dialysate calcium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dialysate calcium at 1.5 mmol/l (Control)
Study: 22235139
Drug: Brivaracetam 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brivaracetam 200 mg single oral dose
Study: 21039672
Drug: Velusetrag 15
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velusetrag 15 mg
Study: 21039672
Drug: Velusetrag 30
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velusetrag 30 mg
Study: 21039672
Drug: Velusetrag 50
Normalized name: Velusetrag
DrugBank: Velusetrag (DB12702)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velusetrag 50 mg
Study: 10529044
Drug: metered-dose inhaler
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: metered-dose inhaler and Volumatic
Study: 25347936
Drug: Hyaluronidase group
Normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hyaluronidase group (ropivacaine 0.5% with 100 IU/ml of hyaluronidase)
Study: 23777849
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation (0.48‐1000 μmol/L, 4 inhalations per dose)
Study: 23777849
Drug: Capsaicin inhalation
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Capsaicin inhalation
Study: 15297192
Drug: Cisplatin and
Normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin and irinotecan (25 mg/m² and 65 mg/m² weekly for three consecutive weeks, repeated every 28 days)
Study: 3535022
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) administered twice daily
Study: 3535022
Drug: Colloidal bismuth
Normalized name: Colloidal bismuth subcitrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colloidal bismuth subcitrate (CBS) administered four times daily
Study: 31865665
Drug: Mobilization and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobilization and SACS injection
Study: 31865665
Drug: SACS injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: SACS injection only
Study: 19597646
Drug: Cefepime (CFP)
DrugBank: Cefepime (DB01413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefepime (CFP) monotherapy
Study: 17065275
Drug: Topical cord
Normalized name: Bos taurus umbilical cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cord applications of mustard oil
Study: 17065275
Drug: Topical applications
Normalized name: honey based topical applications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical applications of other potentially unclean substances
Study: 12512233
Drug: Losartan (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (50 mg/daily per oral)
Study: 2696483
Drug: Inadine (rayon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inadine (rayon dressing with 10 per cent povidone iodine ointment)
Study: 19380660
Drug: Acitretin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (25 mg) plus Pioglitazone hydrochloride (15 mg)
Study: 19380660
Drug: Acitretin (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acitretin (25 mg) plus placebo
Study: 11352437
Drug: Single 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 200mg oral dose of moxifloxacin
Study: 3296721
Drug: Diet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet treatment and one of five active drug regimens (enalapril, doxazosin, acebutolol, amlodipine, chlorthalidone)
Study: 3296721
Drug: Diet treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet treatment alone
Study: 29335748
Drug: Hydrogel implant
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogel implant (Cartiva™)
Study: 25004265
Drug: Norepinephrine (NE)
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Norepinephrine (NE) infusion (0.15 mcg/kg/min)
Study: 10228257
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline infusion (placebo)
Study: 1461625
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate at a dose of 480 mg/day for 3-4 months
Study: 1461625
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate at a dose of 160 mg/day for 3-4 months
Study: 1461625
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (combined data for both doses)
Study: 6428619
Drug: Insulin (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin (up to 48 units of highly purified porcine lente insulin)
Study: 31697453
Drug: Oral health
Normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral health program including individual oral hygiene monitoring for 2 months, awareness sessions, practical demonstration of toothbrushing and adaptive techniques with role-play.
Study: 28190468
Drug: 1% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% w/w CA-oil lotion
Study: 28190468
Drug: 5% w/w
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% w/w CA-oil lotion
Study: 28190468
Drug: Placebo (base-lotion)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (base-lotion)
Study: 29989857
Drug: Intensity‐modulated radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity‐modulated radiation therapy (IMRT)
Study: 27259317
Drug: Conventional radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional radiation therapy (CRT)
Study: 23880258
Drug: 2% chlorhexidine
Normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% chlorhexidine (CHX) gel (G2)
Study: 23880258
Drug: 2% CHX
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% CHX gel + Ca(OH)2 (G4)
Study: 23880258
Drug: 2-visit treatment
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2-visit treatment (G3 and G4)
Study: 23880258
Drug: 1-visit treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-visit treatment (G1 and G2)
Study: 21972642
Drug: Acupuncture knife
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture knife therapy
Study: 21972642
Drug: Blocking therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blocking therapy
Study: 16915770
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) analysis in CAD patients without MI
Study: 16915770
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) analysis in CAD patients with MI
Study: 16915770
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) analysis in CAD patients with MI and VT
Study: 16915770
Drug: Magnetocardiography (MCG)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnetocardiography (MCG) analysis in healthy subjects
Study: 14623061
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg tibolone
Study: 12207627
Drug: 1.25 mg
Normalized name: menthol 1.25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg and 2.5 mg tibolone
Study: 10509987
Drug: Preoperative IABP
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative IABP therapy starting 2 hours (T2), 12 hours (T12), or 24 hours (T24) before the operation.
Study: 19635155
Drug: Preoperative IABP
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative IABP therapy
Study: 2031517
Drug: Ofloxacin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin (300 mg, taken twice daily for 7 days)
Study: 7198936
Drug: Combination chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination chemotherapy of vincristine, bleomycin, methotrexate, hydrocortisone, and 5-fluorouracil given over 24 hours every 2 to 3 weeks.
Study: 7198936
Drug: Chemotherapy before
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy before radiation therapy or surgery.
Study: 7198936
Drug: Primary adjuvant
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary adjuvant chemotherapy without cis-platinum.
Study: 24049896
Drug: Direct fluorescent
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct fluorescent antibody test
Study: 22492244
Drug: HPV-16/18 virus-like
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV-16/18 virus-like particle vaccine
Study: 15793272
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral treatment (CBT) combined with asthma education (AE)
Study: 8912130
Drug: Intravenous ticarcillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ticarcillin and clavulinic acid (Timentin) pre-ERCP (group I)
Study: 8912130
Drug: Intravenous ticarcillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ticarcillin and clavulinic acid (Timentin) plus 3 days of oral amoxycillin and clavulinic acid (Augmentin) (group II)
Study: 1811329
Drug: Nizoral cream
DrugBank: Ketoconazole (DB01026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nizoral cream containing ketoconazole
Study: 7039814
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C and D (DC containing)
Study: 576879
Drug: Treatment D
Normalized name: Earwax Treatment Drops
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment D
Study: 7039814
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (FU + ME)
Study: 26467358
Drug: Metoprolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (1 x 50 mg)
Study: 26467358
Drug: Carvedilol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (2 x 12.5 mg)
Study: 22205496
Drug: Budiodarone 400
Normalized name: Budiodarone
DrugBank: Budiodarone (DB05519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budiodarone 400 mg BID
Study: 22205496
Drug: Budiodarone 600
Normalized name: Budiodarone
DrugBank: Budiodarone (DB05519)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budiodarone 600 mg BID
Study: 12122920
Drug: 5-HT3 receptor
Normalized name: 5-HT3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonists
Study: 17239324
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of a 5-HT3 antagonist, steroids, and aprepitant
Study: 15598679
Drug: AA/CHO supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: AA/CHO supplement
Study: 12753445
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 0.5 ml.kg‐1
Study: 12753445
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.25% bupivacaine 0.5 ml.kg‐1 with 1 microg x kg‐1 neostigmine
Study: 25249361
Drug: Placebo ultrasound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ultrasound treatment
Study: 7389058
Drug: Low-dose cyclophosphamide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cyclophosphamide (CTX) 100 mg/day continuously
Study: 7389058
Drug: Adriamycin (ADM)
Normalized name: Adriamycin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adriamycin (ADM) 50 mg/m2 IV every 4 weeks plus CTX 100 mg/day
Study: 27457790
Drug: Polysaccharide-resin-honey based
Normalized name: Honey
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polysaccharide-resin-honey based cough syrup
Study: 27457790
Drug: Carbocysteine syrup
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbocysteine syrup
Study: 16478844
Drug: Interdisciplinary intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interdisciplinary intervention group receiving medical care, asthma education, and problem-solving therapy (n = 89)